Tianjin Xinglian Peptide Biotechnology
ConjuStar focuses on developing next generation innovative oncology therapies.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD77—115m (Dealroom.co estimates Jan 2024.)
Shanghai Shanghai (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY55.0m | Seed | |
* | CNY90.0m | Seed | |
| Total Funding | AUD30.8m | ||